Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	MAP-kinase scaffold activity	MAP2K1 MAP2K2	2.57e-04	13	37	2	GO:0005078
GeneOntologyMolecularFunction	MAP kinase kinase activity	MAP2K1 MAP2K2	5.02e-04	18	37	2	GO:0004708
GeneOntologyBiologicalProcess	trachea morphogenesis	RSPO2 MAP2K1 MAP2K2	1.16e-06	12	37	3	GO:0060439
GeneOntologyBiologicalProcess	trachea development	RSPO2 MAP2K1 MAP2K2	7.99e-06	22	37	3	GO:0060438
GeneOntologyBiologicalProcess	regulation of Golgi inheritance	MAP2K1 MAP2K2	1.87e-05	4	37	2	GO:0090170
GeneOntologyBiologicalProcess	cell morphogenesis involved in neuron differentiation	ETV1 UNC5A CLASP2 PPP3CA MAP2K1 MAP2K2 FZD3 WDR47	4.37e-05	748	37	8	GO:0048667
GeneOntologyBiologicalProcess	axonogenesis	ETV1 UNC5A CLASP2 MAP2K1 MAP2K2 FZD3 WDR47	5.68e-05	566	37	7	GO:0007409
GeneOntologyBiologicalProcess	trachea formation	MAP2K1 MAP2K2	6.54e-05	7	37	2	GO:0060440
GeneOntologyBiologicalProcess	neuron projection morphogenesis	ETV1 UNC5A CLASP2 PPP3CA MAP2K1 MAP2K2 FZD3 WDR47	7.15e-05	802	37	8	GO:0048812
GeneOntologyBiologicalProcess	plasma membrane bounded cell projection morphogenesis	ETV1 UNC5A CLASP2 PPP3CA MAP2K1 MAP2K2 FZD3 WDR47	8.28e-05	819	37	8	GO:0120039
GeneOntologyBiologicalProcess	cell projection morphogenesis	ETV1 UNC5A CLASP2 PPP3CA MAP2K1 MAP2K2 FZD3 WDR47	8.78e-05	826	37	8	GO:0048858
GeneOntologyBiologicalProcess	axon development	ETV1 UNC5A CLASP2 MAP2K1 MAP2K2 FZD3 WDR47	1.25e-04	642	37	7	GO:0061564
GeneOntologyBiologicalProcess	epithelial cell proliferation involved in lung morphogenesis	MAP2K1 MAP2K2	2.04e-04	12	37	2	GO:0060502
GeneOntologyBiologicalProcess	ERBB2-ERBB3 signaling pathway	MAP2K1 MAP2K2	2.41e-04	13	37	2	GO:0038133
GeneOntologyBiologicalProcess	ERBB3 signaling pathway	MAP2K1 MAP2K2	2.81e-04	14	37	2	GO:0038129
GeneOntologyBiologicalProcess	lung morphogenesis	RSPO2 MAP2K1 MAP2K2	3.55e-04	77	37	3	GO:0060425
GeneOntologyBiologicalProcess	regulation of Golgi organization	MAP2K1 MAP2K2	4.70e-04	18	37	2	GO:1903358
GeneOntologyBiologicalProcess	regulation of early endosome to late endosome transport	MAP2K1 MAP2K2	5.83e-04	20	37	2	GO:2000641
GeneOntologyCellularComponent	glutamatergic synapse	KCNAB2 PLEKHA5 UBE2M CLASP2 PPP3CA BSN MAP2K1 FZD3	9.07e-05	817	38	8	GO:0098978
GeneOntologyCellularComponent	postsynapse	KCNAB2 PLEKHA5 UBE2M PPP3CA BSN MAP2K1 DNAJC6 RPL17	4.08e-04	1018	38	8	GO:0098794
HumanPheno	Aplasia/Hypoplasia affecting the eye	KCNAB2 DNAAF2 RSPO2 PPP3CA LMBRD2 MAP2K1 DNAJC6 MAP2K2	5.94e-05	1183	9	8	HP:0008056
HumanPheno	Cubitus valgus	LMBRD2 MAP2K1 MAP2K2	8.55e-05	53	9	3	HP:0002967
Domain	TSP1	ADAMTS16 RSPO2 UNC5A	2.87e-04	65	37	3	SM00209
Domain	TSP1_rpt	ADAMTS16 RSPO2 UNC5A	2.87e-04	65	37	3	IPR000884
Domain	TSP1	ADAMTS16 RSPO2 UNC5A	2.87e-04	65	37	3	PS50092
Domain	TSP_1	ADAMTS16 UNC5A	6.91e-03	63	37	2	PF00090
Pathway	PID_NETRIN_PATHWAY	UNC5A MAP2K1 MAP2K2	3.73e-05	32	29	3	M108
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_BRAF_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.07e-05	5	29	2	M49016
Pathway	BIOCARTA_FMLP_PATHWAY	PPP3CA MAP2K1 MAP2K2	4.49e-05	34	29	3	M10287
Pathway	BIOCARTA_FMLP_PATHWAY	PPP3CA MAP2K1 MAP2K2	4.49e-05	34	29	3	MM1399
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	MAP2K1 MAP2K2	6.10e-05	6	29	2	M27559
Pathway	REACTOME_NEGATIVE_FEEDBACK_REGULATION_OF_MAPK_PATHWAY	MAP2K1 MAP2K2	6.10e-05	6	29	2	MM15273
Pathway	KEGG_MEDICUS_PATHOGEN_YERSINIA_YOPP_J_TO_TLR2_4_MAPK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	6.10e-05	6	29	2	M47636
Pathway	REACTOME_NERVOUS_SYSTEM_DEVELOPMENT	UNC5A CASC3 CLASP2 MAP2K1 MAP2K2 PSMA2 RPL17	1.29e-04	575	29	7	M29853
Pathway	WP_ETHANOL_METABOLISM_PRODUCTION_OF_ROS_BY_CYP2E1	MAP2K1 MAP2K2	1.46e-04	9	29	2	M39481
Pathway	WP_ALZHEIMERS_DISEASE	PPP3CA MAP2K1 MAP2K2 FZD3 PSMA2	1.73e-04	261	29	5	M42565
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KRAS_NRAS_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	1.82e-04	10	29	2	M47374
Pathway	KEGG_MEDICUS_VARIANT_HRAS_OVEREXPRESSION_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	1.82e-04	10	29	2	M47420
Pathway	WP_ETHANOL_METABOLISM_RESULTING_IN_PRODUCTION_OF_ROS_BY_CYP2E1	MAP2K1 MAP2K2	1.82e-04	10	29	2	MM15821
Pathway	KEGG_MEDICUS_REFERENCE_RAC_CDC42_PAK_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	1.82e-04	10	29	2	M47735
Pathway	WP_CARDIAC_HYPERTROPHIC_RESPONSE	PPP3CA MAP2K1 MAP2K2	1.91e-04	55	29	3	M39685
Pathway	KEGG_MEDICUS_VARIANT_RET_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.22e-04	11	29	2	M47370
Pathway	KEGG_MEDICUS_VARIANT_TRK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.22e-04	11	29	2	M47371
Pathway	REACTOME_UPTAKE_AND_FUNCTION_OF_ANTHRAX_TOXINS	MAP2K1 MAP2K2	2.22e-04	11	29	2	M27420
Pathway	KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.66e-04	12	29	2	M47369
Pathway	KEGG_MEDICUS_PATHOGEN_HBV_LHBS_TO_PKC_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.66e-04	12	29	2	M47597
Pathway	KEGG_MEDICUS_ENV_FACTOR_METALS_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	2.66e-04	12	29	2	M47815
Pathway	PID_CD8_TCR_DOWNSTREAM_PATHWAY	PPP3CA MAP2K1 MAP2K2	3.14e-04	65	29	3	M272
Pathway	KEGG_MEDICUS_PATHOGEN_HCV_CORE_TO_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.14e-04	13	29	2	M47589
Pathway	BIOCARTA_CDK5_PATHWAY	MAP2K1 MAP2K2	3.14e-04	13	29	2	M89
Pathway	BIOCARTA_BARR_MAPK_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M668
Pathway	KEGG_MEDICUS_VARIANT_BCR_ABL_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47364
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KIT_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47365
Pathway	KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47366
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47378
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_PLCG_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47383
Pathway	KEGG_MEDICUS_VARIANT_EML4_ALK_FUSION_KINASE_TO_PLCG_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47384
Pathway	REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS	MAP2K1 MAP2K2	3.66e-04	14	29	2	M622
Pathway	REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS	MAP2K1 MAP2K2	3.66e-04	14	29	2	MM14667
Pathway	BIOCARTA_CDK5_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	MM1457
Pathway	KEGG_MEDICUS_VARIANT_MET_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	M47488
Pathway	BIOCARTA_BARR_MAPK_PATHWAY	MAP2K1 MAP2K2	3.66e-04	14	29	2	MM1489
Pathway	KEGG_LONG_TERM_POTENTIATION	PPP3CA MAP2K1 MAP2K2	3.91e-04	70	29	3	M3115
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_MET_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47367
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47375
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_PLCG_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47382
Pathway	KEGG_MEDICUS_VARIANT_AMPLIFIED_FGFR_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47380
Pathway	KEGG_MEDICUS_REFERENCE_CA2_PYK2_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47592
Pathway	KEGG_MEDICUS_PATHOGEN_HBV_HBX_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47593
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_FGF17_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47640
Pathway	KEGG_MEDICUS_VARIANT_IGF2_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47485
Pathway	KEGG_MEDICUS_REFERENCE_HGF_MET_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47473
Pathway	KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47474
Pathway	KEGG_MEDICUS_REFERENCE_TGFA_EGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47480
Pathway	KEGG_MEDICUS_VARIANT_EGF_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47495
Pathway	KEGG_MEDICUS_REFERENCE_EREG_EGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47496
Pathway	KEGG_MEDICUS_REFERENCE_AREG_EGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47497
Pathway	KEGG_MEDICUS_REFERENCE_KITLG_KIT_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47472
Pathway	KEGG_MEDICUS_PATHOGEN_HCMV_GB_TO_PDGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47535
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_EGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.22e-04	15	29	2	M47531
Pathway	KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY	PPP3CA MAP2K1 MAP2K2	4.78e-04	75	29	3	M5436
Pathway	KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47363
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_FGFR3_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47373
Pathway	KEGG_MEDICUS_REFERENCE_EGF_ERBB2_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47381
Pathway	KEGG_MEDICUS_REFERENCE_P4_PR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47804
Pathway	KEGG_MEDICUS_ENV_FACTOR_E2_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47801
Pathway	WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER	MAP2K1 MAP2K2	4.82e-04	16	29	2	M39882
Pathway	KEGG_MEDICUS_REFERENCE_IGF_IGF1R_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47483
Pathway	KEGG_MEDICUS_REFERENCE_AGE_RAGE_SIGNALING_PATHWAY	MAP2K1 MAP2K2	4.82e-04	16	29	2	M47682
Pathway	WP_ALZHEIMERS_DISEASE_AND_MIRNA_EFFECTS	PPP3CA MAP2K1 MAP2K2 FZD3 PSMA2	4.82e-04	326	29	5	M39379
Pathway	KEGG_VEGF_SIGNALING_PATHWAY	PPP3CA MAP2K1 MAP2K2	4.97e-04	76	29	3	M1749
Pathway	WP_ERK_PATHWAY_IN_HUNTINGTONS_DISEASE	MAP2K1 MAP2K2	5.45e-04	17	29	2	M39564
Pathway	KEGG_MEDICUS_REFERENCE_PDGF_PDGFR_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	M47376
Pathway	BIOCARTA_HCMV_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	M8353
Pathway	BIOCARTA_HCMV_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	MM1408
Pathway	BIOCARTA_BARRESTIN_SRC_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	M111
Pathway	WP_IL9_SIGNALING	MAP2K1 MAP2K2	5.45e-04	17	29	2	M39644
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_AGE_RAGE_SIGNALING_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	M47684
Pathway	SA_TRKA_RECEPTOR	MAP2K1 MAP2K2	5.45e-04	17	29	2	M18895
Pathway	BIOCARTA_BARRESTIN_SRC_PATHWAY	MAP2K1 MAP2K2	5.45e-04	17	29	2	MM1491
Pathway	PID_ANTHRAX_PATHWAY	MAP2K1 MAP2K2	6.13e-04	18	29	2	M267
Pathway	BIOCARTA_MAL_PATHWAY	MAP2K1 MAP2K2	6.13e-04	18	29	2	MM1482
Pathway	WP_SEROTONIN_RECEPTOR_467_AND_NR3C_SIGNALING	MAP2K1 MAP2K2	6.84e-04	19	29	2	M39358
Pathway	KEGG_MEDICUS_REFERENCE_CXCL12_CXCR4_PKC_ERK_SIGNALING_PATHAWAY	MAP2K1 MAP2K2	6.84e-04	19	29	2	M47596
Pathway	KEGG_MEDICUS_ENV_FACTOR_NNK_NNN_TO_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	6.84e-04	19	29	2	M47793
Pathway	KEGG_MEDICUS_REFERENCE_WNT_SIGNALING_MODULATION_LGR_RSPO	RSPO2 FZD3	6.84e-04	19	29	2	M47833
Pathway	REACTOME_SIGNAL_TRANSDUCTION_BY_L1	MAP2K1 MAP2K2	6.84e-04	19	29	2	MM15113
Pathway	BIOCARTA_MAL_PATHWAY	MAP2K1 MAP2K2	6.84e-04	19	29	2	M10547
Pathway	WP_SEROTONIN_RECEPTOR_2_AND_ELKSRFGATA4_SIGNALING	MAP2K1 MAP2K2	7.59e-04	20	29	2	M39485
Pathway	KEGG_MEDICUS_REFERENCE_ACH_CHRN_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	8.38e-04	21	29	2	M47792
Pathway	KEGG_MEDICUS_REFERENCE_GNRH_GNRHR_PLCB_PKC_SIGNALING_PATHWAY	MAP2K1 MAP2K2	8.38e-04	21	29	2	M47638
Pathway	REACTOME_SIGNAL_TRANSDUCTION_BY_L1	MAP2K1 MAP2K2	8.38e-04	21	29	2	M878
Pathway	WP_GNAQ_PATHWAYS_IN_PORTWINE_STAIN	MAP2K1 MAP2K2	8.38e-04	21	29	2	M48342
Pathway	REACTOME_CLEC7A_DECTIN_1_SIGNALING	UBE2M PPP3CA PSMA2	8.97e-04	93	29	3	MM15204
Pathway	REACTOME_RAF_INDEPENDENT_MAPK1_3_ACTIVATION	MAP2K1 MAP2K2	9.20e-04	22	29	2	MM14506
Pathway	REACTOME_SIGNALING_BY_ROBO_RECEPTORS	CASC3 CLASP2 PSMA2 RPL17	9.75e-04	218	29	4	M2780
Pathway	KEGG_MEDICUS_REFERENCE_E2_ER_RAS_ERK_SIGNALING_PATHWAY	MAP2K1 MAP2K2	1.01e-03	23	29	2	M47799
Pathway	REACTOME_RAF_INDEPENDENT_MAPK1_3_ACTIVATION	MAP2K1 MAP2K2	1.01e-03	23	29	2	M26917
Pathway	WP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY	PPP3CA MAP2K1 MAP2K2	1.08e-03	99	29	3	MM15905
Pathway	REACTOME_CLEC7A_DECTIN_1_SIGNALING	UBE2M PPP3CA PSMA2	1.11e-03	100	29	3	M27467
Pathway	KEGG_MELANOGENESIS	MAP2K1 MAP2K2 FZD3	1.14e-03	101	29	3	M7761
Pathway	WP_THYROXINE_THYROID_HORMONE_PRODUCTION	MAP2K1 MAP2K2	1.19e-03	25	29	2	M39353
Pathway	WP_4HYDROXYTAMOXIFEN_DEXAMETHASONE_AND_RETINOIC_ACIDS_REGULATION_OF_P27_EXPRESSION	MAP2K1 MAP2K2	1.19e-03	25	29	2	M39574
Pathway	WP_NOVEL_JUNDMP1_PATHWAY	MAP2K1 MAP2K2	1.19e-03	25	29	2	MM15984
Pathway	WP_IL7_SIGNALING	MAP2K1 MAP2K2	1.19e-03	25	29	2	M39499
Pathway	WP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY	PPP3CA MAP2K1 MAP2K2	1.24e-03	104	29	3	M39625
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	KCNAB2 CASC3 PLEKHA5 CLASP2 PPP3CA BSN TRA2B DNAJC6 WDR47	7.30e-07	963	38	9	28671696
Pubmed	Lung development requires an active ERK/MAPK pathway in the lung mesenchyme.	RSPO2 MAP2K1 MAP2K2	9.71e-07	18	38	3	27748998
Pubmed	Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.	MAP2K1 MAP2K2	1.16e-06	2	38	2	9563949
Pubmed	Activation of two isoforms of mitogen-activated protein kinase kinase in response to epidermal growth factor and nerve growth factor.	MAP2K1 MAP2K2	1.16e-06	2	38	2	8529659
Pubmed	Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation.	MAP2K1 MAP2K2	1.16e-06	2	38	2	21699731
Pubmed	Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia.	MAP2K1 MAP2K2	1.16e-06	2	38	2	17419998
Pubmed	Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product.	MAP2K1 MAP2K2	1.16e-06	2	38	2	1381507
Pubmed	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.	MAP2K1 MAP2K2	1.16e-06	2	38	2	27956260
Pubmed	[Mek1 and Mek2 functions in the formation of the blood placental barrier].	MAP2K1 MAP2K2	1.16e-06	2	38	2	22549869
Pubmed	Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.	MAP2K1 MAP2K2	1.16e-06	2	38	2	17981815
Pubmed	The ERK1/2 pathway regulates testosterone synthesis by coordinately regulating the expression of steroidogenic genes in Leydig cells.	MAP2K1 MAP2K2	1.16e-06	2	38	2	23480967
Pubmed	Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.	MAP2K1 MAP2K2	1.16e-06	2	38	2	23237773
Pubmed	Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells.	MAP2K1 MAP2K2	1.16e-06	2	38	2	28746311
Pubmed	Mek2 is dispensable for mouse growth and development.	MAP2K1 MAP2K2	1.16e-06	2	38	2	12832465
Pubmed	MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response.	MAP2K1 MAP2K2	1.16e-06	2	38	2	23735655
Pubmed	Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases.	MAP2K1 MAP2K2	1.16e-06	2	38	2	30087384
Pubmed	Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19014680
Pubmed	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.	MAP2K1 MAP2K2	1.16e-06	2	38	2	35069558
Pubmed	Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.	MAP2K1 MAP2K2	1.16e-06	2	38	2	22833572
Pubmed	Cisplatin inhibits MEK1/2.	MAP2K1 MAP2K2	1.16e-06	2	38	2	26155939
Pubmed	Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19198628
Pubmed	ERK1/2 can feedback-regulate cellular MEK1/2 levels.	MAP2K1 MAP2K2	1.16e-06	2	38	2	26163823
Pubmed	The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.	MAP2K1 MAP2K2	1.16e-06	2	38	2	21527500
Pubmed	Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo.	MAP2K1 MAP2K2	1.16e-06	2	38	2	15979847
Pubmed	ERK (MAPK) does not phosphorylate tau under physiological conditions in vivo or in vitro.	MAP2K1 MAP2K2	1.16e-06	2	38	2	25491074
Pubmed	Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19383924
Pubmed	Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2.	MAP2K1 MAP2K2	1.16e-06	2	38	2	20172001
Pubmed	Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.	MAP2K1 MAP2K2	1.16e-06	2	38	2	10828601
Pubmed	Omics profiling identifies the regulatory functions of the MAPK/ERK pathway in nephron progenitor metabolism.	MAP2K1 MAP2K2	1.16e-06	2	38	2	36189831
Pubmed	MEK1 and MEK2, different regulators of the G1/S transition.	MAP2K1 MAP2K2	1.16e-06	2	38	2	15284233
Pubmed	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.16e-06	2	38	2	22805292
Pubmed	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.	MAP2K1 MAP2K2	1.16e-06	2	38	2	22805291
Pubmed	Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.	MAP2K1 MAP2K2	1.16e-06	2	38	2	26625317
Pubmed	Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19156172
Pubmed	Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway.	MAP2K1 MAP2K2	1.16e-06	2	38	2	35975983
Pubmed	p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2.	MAP2K1 MAP2K2	1.16e-06	2	38	2	12839928
Pubmed	Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc.	MAP2K1 MAP2K2	1.16e-06	2	38	2	16162927
Pubmed	Implication of MEK1 and MEK2 in the establishment of the blood-placenta barrier during placentogenesis in mouse.	MAP2K1 MAP2K2	1.16e-06	2	38	2	22561024
Pubmed	Regulation of intracellular MEK1/2 translocation in mouse oocytes: cytoplasmic dynein/dynactin-mediated poleward transport and cyclin B degradation-dependent release from spindle poles.	MAP2K1 MAP2K2	1.16e-06	2	38	2	17507801
Pubmed	MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.	MAP2K1 MAP2K2	1.16e-06	2	38	2	16957420
Pubmed	Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.	MAP2K1 MAP2K2	1.16e-06	2	38	2	15543157
Pubmed	T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3',5'-cyclic monophosphate.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19144315
Pubmed	Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.	MAP2K1 MAP2K2	1.16e-06	2	38	2	19500021
Pubmed	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.	MAP2K1 MAP2K2	1.16e-06	2	38	2	22197931
Pubmed	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	MAP2K1 MAP2K2	1.16e-06	2	38	2	18390968
Pubmed	Etv transcription factors functionally diverge from their upstream FGF signaling in lens development.	ETV1 MAP2K1 MAP2K2	2.40e-06	24	38	3	32043969
Pubmed	FGF-induced Pea3 transcription factors program the genetic landscape for cell fate determination.	ETV1 MAP2K1 MAP2K2	2.40e-06	24	38	3	30188892
Pubmed	Proteomic analysis of NMDA receptor-adhesion protein signaling complexes.	PPP3CA BSN MAP2K1 MAP2K2	2.41e-06	86	38	4	10862698
Pubmed	Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector.	MAP2K1 MAP2K2	3.48e-06	3	38	2	10489373
Pubmed	Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.	MAP2K1 MAP2K2	3.48e-06	3	38	2	20885957
Pubmed	Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions.	MAP2K1 MAP2K2	3.48e-06	3	38	2	23626836
Pubmed	Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress.	MAP2K1 MAP2K2	3.48e-06	3	38	2	15292274
Pubmed	Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene.	MAP2K1 MAP2K2	3.48e-06	3	38	2	25463315
Pubmed	Lactoferrin interacts with SPLUNC1 to attenuate lipopolysaccharide-induced inflammation of human nasal epithelial cells via down-regulated MEK1/2-MAPK signaling.	MAP2K1 MAP2K2	3.48e-06	3	38	2	28178421
Pubmed	The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation.	MAP2K1 MAP2K2	3.48e-06	3	38	2	34715128
Pubmed	Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.	MAP2K1 MAP2K2	3.48e-06	3	38	2	11823456
Pubmed	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.	MAP2K1 MAP2K2	3.48e-06	3	38	2	25600339
Pubmed	Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.	MAP2K1 MAP2K2	3.48e-06	3	38	2	18060073
Pubmed	MEK1 dependent and independent ERK activation regulates IL-10 and IL-12 production in bone marrow derived macrophages.	MAP2K1 MAP2K2	3.48e-06	3	38	2	26208884
Pubmed	Regulation of skeletal muscle insulin-stimulated signaling through the MEK-REDD1-mTOR axis.	MAP2K1 MAP2K2	3.48e-06	3	38	2	27913296
Pubmed	Anesthesia-induced hypothermia mediates decreased ARC gene and protein expression through ERK/MAPK inactivation.	MAP2K1 MAP2K2	3.48e-06	3	38	2	24045785
Pubmed	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.	MAP2K1 MAP2K2	3.48e-06	3	38	2	27636997
Pubmed	Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.	MAP2K1 MAP2K2	3.48e-06	3	38	2	34026451
Pubmed	Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.	MAP2K1 MAP2K2	3.48e-06	3	38	2	17101779
Pubmed	Mitogen-activated protein kinase kinases promote mitochondrial biogenesis in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression.	MAP2K1 MAP2K2	3.48e-06	3	38	2	21458501
Pubmed	Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation.	MAP2K1 MAP2K2	3.48e-06	3	38	2	25218145
Pubmed	Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.	MAP2K1 MAP2K2	3.48e-06	3	38	2	22393900
Pubmed	Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?	MAP2K1 MAP2K2	3.48e-06	3	38	2	12612059
Pubmed	Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.	MAP2K1 MAP2K2	3.48e-06	3	38	2	16439621
Pubmed	p38mapk and MEK1/2 inhibition contribute to cellular oxidant injury after hypoxia.	MAP2K1 MAP2K2	3.48e-06	3	38	2	14672918
Pubmed	MEK1/2 activity modulates TREM2 cell surface recruitment.	MAP2K1 MAP2K2	3.48e-06	3	38	2	33839686
Pubmed	MEK1,2 response element mediates angiotensin II-stimulated plasminogen activator inhibitor-1 promoter activation.	MAP2K1 MAP2K2	3.48e-06	3	38	2	14656894
Pubmed	Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.	MAP2K1 MAP2K2	3.48e-06	3	38	2	24746703
Pubmed	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	MAP2K1 MAP2K2	3.48e-06	3	38	2	25722381
Pubmed	Epicardium and myocardium separate from a common precursor pool by crosstalk between bone morphogenetic protein- and fibroblast growth factor-signaling pathways.	MAP2K1 MAP2K2	3.48e-06	3	38	2	19628790
Pubmed	Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.	MAP2K1 MAP2K2	3.48e-06	3	38	2	18413255
Pubmed	Specific functions for ERK/MAPK signaling during PNS development.	ETV1 MAP2K1 MAP2K2	5.30e-06	31	38	3	21220101
Pubmed	Alx4 relays sequential FGF signaling to induce lacrimal gland morphogenesis.	ETV1 MAP2K1 MAP2K2	5.84e-06	32	38	3	29028795
Pubmed	Differential expression of MEK1 and MEK2 during mouse development.	MAP2K1 MAP2K2	6.96e-06	4	38	2	9149902
Pubmed	Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.	MAP2K1 MAP2K2	6.96e-06	4	38	2	8226933
Pubmed	HIV Nef increases T cell ERK MAP kinase activity.	MAP2K1 MAP2K2	6.96e-06	4	38	2	11726657
Pubmed	A conserved docking site in MEKs mediates high-affinity binding to MAP kinases and cooperates with a scaffold protein to enhance signal transmission.	MAP2K1 MAP2K2	6.96e-06	4	38	2	11134045
Pubmed	Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.	MAP2K1 MAP2K2	6.96e-06	4	38	2	17704260
Pubmed	Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis.	MAP2K1 MAP2K2	6.96e-06	4	38	2	28225038
Pubmed	Activation of a Src-dependent Raf-MEK1/2-ERK signaling pathway is required for IL-1alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells.	MAP2K1 MAP2K2	6.96e-06	4	38	2	12063167
Pubmed	Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.	MAP2K1 MAP2K2	6.96e-06	4	38	2	18042262
Pubmed	Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes.	MAP2K1 MAP2K2	6.96e-06	4	38	2	11823472
Pubmed	MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors.	MAP2K1 MAP2K2	6.96e-06	4	38	2	12032872
Pubmed	Lipopolysaccharide induces cytokine production and decreases extravillous trophoblast invasion through a mitogen-activated protein kinase-mediated pathway: possible mechanisms of first trimester placental dysfunction.	MAP2K1 MAP2K2	6.96e-06	4	38	2	22052387
Pubmed	The ERK signaling cascade--views from different subcellular compartments.	MAP2K1 MAP2K2	6.96e-06	4	38	2	19565474
Pubmed	A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.	MAP2K1 MAP2K2	6.96e-06	4	38	2	8385802
Pubmed	Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus.	MAP2K1 MAP2K2	6.96e-06	4	38	2	18617556
Pubmed	Doxycycline up-regulates the expression of IL-6 and GM-CSF via MAPK/ERK and NF-κB pathways in mouse thymic epithelial cells.	MAP2K1 MAP2K2	6.96e-06	4	38	2	21439396
Pubmed	RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.	MAP2K1 MAP2K2	6.96e-06	4	38	2	19816936
Pubmed	Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis.	MAP2K1 MAP2K2	6.96e-06	4	38	2	22946697
Pubmed	Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.	MAP2K1 MAP2K2	6.96e-06	4	38	2	22298595
Pubmed	Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.	MAP2K1 MAP2K2	6.96e-06	4	38	2	23684925
Pubmed	Cardiofaciocutaneous Syndrome	MAP2K1 MAP2K2	6.96e-06	4	38	2	20301365
Pubmed	Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.	MAP2K1 MAP2K2	6.96e-06	4	38	2	21447798
Pubmed	FGF2 Stimulates COUP-TFII Expression via the MEK1/2 Pathway to Inhibit Osteoblast Differentiation in C3H10T1/2 Cells.	MAP2K1 MAP2K2	6.96e-06	4	38	2	27404388
GeneFamily	Mitogen-activated protein kinase kinases	MAP2K1 MAP2K2	4.49e-05	7	27	2	653
Drug	TAK 733	MAP2K1 MAP2K2	2.71e-06	2	38	2	ctd:C558666
Drug	N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide	MAP2K1 MAP2K2	2.71e-06	2	38	2	ctd:C544830
Drug	NIH-3	BSN MAP2K1 MAP2K2	4.08e-06	19	38	3	CID009822007
Drug	RO5126766	MAP2K1 MAP2K2	8.13e-06	3	38	2	ctd:C577924
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	ETV1 PLEKHA5 RIPOR1 DNAJC6 FZD3	1.35e-05	185	38	5	2949_UP
Drug	N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime	MAP2K1 MAP2K2	2.70e-05	5	38	2	ctd:C068836
Drug	AC1L3V8L	MAP2K1 MAP2K2	4.05e-05	6	38	2	CID000122778
Drug	Oleylethanolamide	MAP2K1 MAP2K2	5.67e-05	7	38	2	ctd:C440229
Drug	HWY-289	MAP2K1 MAP2K2	7.55e-05	8	38	2	CID000487138
Drug	2,5-dimethylcelecoxib	MAP2K1 MAP2K2	9.69e-05	9	38	2	ctd:C506698
Drug	vaticanol C	MAP2K1 MAP2K2	9.69e-05	9	38	2	ctd:C459559
Disease	small intestine adenocarcinoma (is_implicated_in)	MAP2K1 MAP2K2	4.59e-06	3	37	2	DOID:4906 (is_implicated_in)
Disease	RASopathy (implicated_via_orthology)	MAP2K1 MAP2K2	5.48e-05	9	37	2	DOID:0080690 (implicated_via_orthology)
Disease	Turner Syndrome, Male	MAP2K1 MAP2K2	8.35e-05	11	37	2	C0041409
Disease	Female Pseudo-Turner Syndrome	MAP2K1 MAP2K2	8.35e-05	11	37	2	C1527404
Disease	Noonan Syndrome 1	MAP2K1 MAP2K2	8.35e-05	11	37	2	C4551602
Disease	Noonan syndrome-like disorder with loose anagen hair	MAP2K1 MAP2K2	2.58e-04	19	37	2	C1843181
Disease	Noonan-Like Syndrome With Loose Anagen Hair	MAP2K1 MAP2K2	2.58e-04	19	37	2	C3501846
Disease	Costello syndrome (disorder)	MAP2K1 MAP2K2	2.58e-04	19	37	2	C0587248
Disease	Cardio-facio-cutaneous syndrome	MAP2K1 MAP2K2	2.58e-04	19	37	2	C1275081
Disease	LEOPARD Syndrome	MAP2K1 MAP2K2	3.48e-04	22	37	2	C0175704
Disease	Noonan Syndrome	MAP2K1 MAP2K2	4.15e-04	24	37	2	C0028326
Disease	Cleft upper lip	RSPO2 PLEKHA5	1.10e-03	39	37	2	C0008924
Disease	Cutaneous Melanoma	MAP2K1 MAP2K2	1.22e-03	41	37	2	C0151779
Disease	Heart Diseases	BSN PSMA2	1.53e-03	46	37	2	C0018799
Disease	idiopathic osteonecrosis of the femoral head	ETV1 DNAJC6	1.95e-03	52	37	2	EFO_1001930
Disease	lymphocyte count	ETV1 RIPOR1 CPXCR1 AKIRIN1 TRA2B MAP2K2	9.16e-03	1464	37	6	EFO_0004587
Disease	acylcarnitine measurement	FZD3 RSBN1L	1.11e-02	127	37	2	EFO_0005059

Protein segments in the cluster

Peptide	Gene	Start	Entry
HDQIMRRYGTRPTSY	AKIRIN1	176	Q9H9L7
YYHMVTIPSGARSIR	ADAMTS16	761	Q8TE57
RVHYYRPLTERMTSG	CPXCR1	201	Q8N123
TRSYMSPERLQGTHY	MAP2K1	226	Q02750
RSYMAPERLQGTHYS	MAP2K2	231	P36507
EYGSMYTVHLGPRRV	CYP2F1	61	P24903
APGREYAGRSSSRYM	DNAAF2	126	Q9NVR5
SGRYRHSMTNLPAYP	DTX2	211	Q86UW9
RSMESNGRPASTHYY	BSN	3306	Q9UPA5
YRYGRSAPRVVHSVM	OR51F1	271	A6NGY5
GMYREGPTYQRRGSL	ETV1	321	P50549
RQTGSPGMIYSTRYG	KCNAB2	16	Q13303
AAGTGRMSAPRNYSR	CASC3	301	O15234
GIGLSPSHRRYLGYM	DNAJC6	201	O75061
RSRDGRYTPCSYRGM	FZD3	591	Q9NPG1
RYIMGRFAFYRHNRP	FOXS1	46	O43638
ASRSQGYPMSAAYGR	KIAA1210	521	Q9ULL0
AGYRMYRKSQTTGFP	PPP3CA	286	Q08209
RYHGHSMSDPGVSYR	PDHA2	286	P29803
RTYSHGTYRAGPMRQ	RSBN1L	451	Q6PCB5
SRKGHMYPVRNYSPT	SELPLG	346	Q14242
RYQPGGRYLSMSRSD	LMBRD2	676	Q68DH5
HFGREYRSPSLGTMR	FN3K	291	Q9H479
RRRTYRAHGRINPYM	RPL17	126	P18621
GYYGHRAPDMNRCAR	RSPO2	81	Q6UXX9
RSYSSRNGSIPTYMR	CLASP2	636	O75122
LYDIRGGRMVQSYHP	WDR47	826	O94967
SYFGSRVHRPRMIGY	SLCO2B1	106	O94956
YSGMGPDYRVLVHRA	PSMA2	76	P25787
YFRSLPRGTSNMTYG	UNC5A	431	Q6ZN44
PSGARVGHRSLMRYY	ZNF622	386	Q969S3
HRAQIMARYPEGYRT	PLEKHA5	446	Q9HAU0
YNMVRAYTTGSPGSR	RIPOR1	161	Q6ZS17
PREYRASGSRRGMAY	PJA1	101	Q8NG27
IYMGRPTYGSSRRRD	TRA2B	206	P62995
RSMRGGYIGSTYFER	UBE2M	166	P61081
GLTYHQRRHTGEMPY	ZNF836	736	Q6ZNA1
GRYGEVMPVYRRDSH	TMED8	271	Q6PL24